Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
September 10 2020 - 9:00AM
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology
company focused on liver-directed treatment of rare primary and
metastatic cancers, today announced management will participate in
two upcoming virtual investor conferences:
- H.C. Wainwright 22nd Annual Global Investment Conference,
presenting on Tuesday, September 15 at 4:30 PM (EDT). A live
webcast of the presentation will be available to the public
at https://wsw.com/webcast/hcw7/dcth/1592203
- Oppenheimer Fall Healthcare Life Science & Med Tech Summit,
participating on September 23, 2020.
Management will be available for virtual one-on-one meetings
during both conferences. To schedule a meeting with management,
please contact your conference representative
or James@HaydenIR.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
Our investigational product Melphalan Hydrochloride for Injection
for use with the Delcath Hepatic Delivery System (Melphalan/HDS) –
is designed to administer high-dose chemotherapy to the liver while
minimizing systemic exposure and associated side effects. In
addition to the Phase 3 FOCUS Trial, we have initiated a global
Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC)
called The ALIGN Trial. We currently are also evaluating other
forms of metastatic liver cancers. Melphalan/HDS has not been
approved by the U.S. Food & Drug Administration (FDA) for sale
in the U.S. In Europe, our system is marketed under the trade name
Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT)
and has been CE Marked and used at major medical centers to treat a
wide range of cancers of the liver. CHEMOSAT is being marketed
under an exclusive licensing agreement with medac GmbH, a privately
held multi-national pharmaceutical company headquartered in Germany
that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Hayden IR James Carbonara (646)-755-7412 james@haydenir.com
Brett Maas (646) 536-7331 brett@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Apr 2023 to Apr 2024